MDxHealth SA (MDXH.BR)

0.646 €

+0.01 (+1.89%)
Rating:
Recommendation:
-
Symbol MDXH.BR
Price 0.646 €
Beta 0.809
Volume Avg. 0.04M
Market Cap 105.221M
Shares () -
52 Week Range 0.59-0.97
1y Target Est -
DCF Unlevered MDXH.BR DCF ->
DCF Levered MDXH.BR LDCF ->
ROE -153.23% Strong Sell
ROA -37.39% Strong Sell
Operating Margin -
Debt / Equity 470.70% Strong Buy
P/E -
P/B 1.88 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Mr. Michael McGarrity
Healthcare
Diagnostics & Research
Brussels

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, the Netherlands, Belgium, Spain, Poland, Italy, rest of European Union, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.